Literature DB >> 30425059

miR-146a Controls Immune Response in the Melanoma Microenvironment.

Justin Mastroianni1,2, Natalie Stickel1, Hana Andrlova1, Kathrin Hanke1,2, Wolfgang Melchinger1, Sandra Duquesne1, Dominik Schmidt1,2, Martina Falk1, Geoffroy Andrieux3, Dietmar Pfeifer1, Heide Dierbach1, Annette Schmitt-Graeff4, Frank Meiss5, Melanie Boerries3, Robert Zeiser6,7.   

Abstract

MicroRNAs (miR) are small noncoding RNAs that regulate gene expression, posttranscription, and manipulate immune responses in different types of cancers. In this study, we identify miR-146a as a negative regulator of immune activation, comparable to immune-checkpoint molecules. miR-146a levels were increased in melanoma microenvironmental tissue, and miR-146a-/- mice survived longer and developed less metastases in comparison with wild-type melanoma-bearing mice. T cells isolated from miR-146a-/- mice revealed higher expression levels of the miR-146a target gene Stat1 and the Stat1-regulated cytokine IFNγ. Neutralization of IFNγ in miR-146a-/- mice decreased survival and increased melanoma metastasis patterns to those of wild-type mice. In vitro, IFNγ reduced melanoma cell migration, cell-cycle activity, and basal metabolic rate. Conversely, IFNγ also increased PD-L1 levels on the melanoma cells, which may counterbalance some of the beneficial effects increasing immune escape in vivo. Combined treatment with a miR-146a antagomiR and anti-PD-1 resulted in improved survival over isotype control or anti-PD-1 treatment alone. In summary, these data show that miR-146a plays a central role within the STAT1/IFNγ axis in the melanoma microenvironment, affecting melanoma migration, proliferation, and mitochondrial fitness as well as PD-L1 levels. Additionally, combined inhibition of PD-1 and miR-146a could be a novel strategy to enhance antitumor immune response elicited by checkpoint therapy. SIGNIFICANCE: These findings identify a microRNA-based mechanism by which melanoma cells escape the immune system, providing a new therapeutic strategy to improve the current management of patients with melanoma. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30425059      PMCID: PMC6330089          DOI: 10.1158/0008-5472.CAN-18-1397

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  MiR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients.

Authors:  S Jiménez-Morales; R Gamboa-Becerra; V Baca; B E Del Río-Navarro; D Y López-Ley; R Velázquez-Cruz; Y Saldaña-Alvarez; G Salas-Martínez; L Orozco
Journal:  Tissue Antigens       Date:  2012-07-24

2.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

3.  CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.

Authors:  Christoph Dürr; Dietmar Pfeifer; Rainer Claus; Annette Schmitt-Graeff; Ulrike V Gerlach; Ralph Graeser; Sophie Krüger; Armin Gerbitz; Robert S Negrin; Jürgen Finke; Robert Zeiser
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

4.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

5.  Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival.

Authors:  Neil Romberg; Henner Morbach; Monica G Lawrence; Sanghyun Kim; Insoo Kang; Steven M Holland; Joshua D Milner; Eric Meffre
Journal:  J Allergy Clin Immunol       Date:  2013-02-10       Impact factor: 10.793

6.  Oncogenic Braf induces melanocyte senescence and melanoma in mice.

Authors:  Nathalie Dhomen; Jorge S Reis-Filho; Silvy da Rocha Dias; Robert Hayward; Kay Savage; Veronique Delmas; Lionel Larue; Catrin Pritchard; Richard Marais
Journal:  Cancer Cell       Date:  2009-04-07       Impact factor: 31.743

7.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

Authors:  C L Nastala; H D Edington; T G McKinney; H Tahara; M A Nalesnik; M J Brunda; M K Gately; S F Wolf; R D Schreiber; W J Storkus
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

8.  Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression.

Authors:  Hana Andrlová; Justin Mastroianni; Josef Madl; Johannes S Kern; Wolfgang Melchinger; Heide Dierbach; Florian Wernet; Marie Follo; Kristin Technau-Hafsi; Cristina Has; Venugopal Rao Mittapalli; Marco Idzko; Ricarda Herr; Tilman Brummer; Hendrik Ungefroren; Hauke Busch; Melanie Boerries; Andreas Narr; Gabriele Ihorst; Claire Vennin; Annette Schmitt-Graeff; Susana Minguet; Paul Timpson; Justus Duyster; Frank Meiss; Winfried Römer; Robert Zeiser
Journal:  Oncotarget       Date:  2017-06-27

9.  MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation.

Authors:  N Stickel; K Hanke; D Marschner; G Prinz; M Köhler; W Melchinger; D Pfeifer; A Schmitt-Graeff; T Brummer; A Heine; P Brossart; D Wolf; N von Bubnoff; J Finke; J Duyster; J Ferrara; U Salzer; R Zeiser
Journal:  Leukemia       Date:  2017-05-09       Impact factor: 11.528

10.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

View more
  28 in total

1.  Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.

Authors:  Pingyan Cheng; Xianghong Chen; Robert Dalton; Alexandra Calescibetta; Tina So; Danielle Gilvary; Grace Ward; Victoria Smith; Sterling Eckard; Judith A Fox; Jeanmarie Guenot; Joseph Markowitz; John L Cleveland; Kenneth L Wright; Alan F List; Sheng Wei; Erika A Eksioglu
Journal:  Mol Ther       Date:  2022-02-09       Impact factor: 12.910

Review 2.  PD-1/PD-L1 pathway: current researches in cancer.

Authors:  Yanyan Han; Dandan Liu; Lianhong Li
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 3.  MicroRNAs in graft-versus-host disease: a review of the latest data.

Authors:  V De Guire; I Ahmad; M Newmarch; E Kostantin; G J Tsongalis; M Guimond; J Roy
Journal:  Bone Marrow Transplant       Date:  2019-12-03       Impact factor: 5.483

Review 4.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 5.  An Emerging Role of miRNAs in Neurodegenerative Diseases: Mechanisms and Perspectives on miR146a.

Authors:  Navneet Ammal Kaidery; Manuj Ahuja; Sudarshana M Sharma; Bobby Thomas
Journal:  Antioxid Redox Signal       Date:  2021-02-15       Impact factor: 7.468

Review 6.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 7.  Significance of 5-S-Cysteinyldopa as a Marker for Melanoma.

Authors:  Kazumasa Wakamatsu; Satoshi Fukushima; Akane Minagawa; Toshikazu Omodaka; Tokimasa Hida; Naohito Hatta; Minoru Takata; Hisashi Uhara; Ryuhei Okuyama; Hironobu Ihn
Journal:  Int J Mol Sci       Date:  2020-01-09       Impact factor: 5.923

8.  miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer.

Authors:  Christos Miliotis; Frank J Slack
Journal:  Cancer Lett       Date:  2021-06-23       Impact factor: 9.756

Review 9.  microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy.

Authors:  Elena Daveri; Elisabetta Vergani; Eriomina Shahaj; Laura Bergamaschi; Stefano La Magra; Michela Dosi; Chiara Castelli; Monica Rodolfo; Licia Rivoltini; Viviana Vallacchi; Veronica Huber
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

10.  Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer.

Authors:  Yuepeng Zhang; Kai Mi; Zhiheng Li; Lixia Qiang; Meiyu Lv; Yushan Wu; Ligong Yuan; Shoude Jin
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.